New Age Alpha Advisors LLC Makes New Investment in Organon & Co. (NYSE:OGN)

New Age Alpha Advisors LLC purchased a new position in shares of Organon & Co. (NYSE:OGN - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 50,517 shares of the company's stock, valued at approximately $754,000.

Several other institutional investors have also modified their holdings of the business. Pacer Advisors Inc. lifted its stake in Organon & Co. by 94,482.1% in the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company's stock valued at $166,391,000 after buying an additional 11,140,388 shares in the last quarter. Weiss Asset Management LP acquired a new position in Organon & Co. in the 3rd quarter worth $32,966,000. Norges Bank acquired a new position in Organon & Co. in the 4th quarter worth $25,258,000. Magnetar Financial LLC increased its holdings in Organon & Co. by 560.2% during the 4th quarter. Magnetar Financial LLC now owns 1,734,434 shares of the company's stock worth $25,878,000 after purchasing an additional 1,471,731 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in shares of Organon & Co. by 303.8% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,242,135 shares of the company's stock valued at $23,762,000 after purchasing an additional 934,505 shares in the last quarter. Institutional investors own 77.43% of the company's stock.

Organon & Co. Stock Performance

OGN stock traded down $0.30 during mid-day trading on Thursday, hitting $14.42. 3,051,888 shares of the company were exchanged, compared to its average volume of 2,557,993. Organon & Co. has a 1-year low of $13.87 and a 1-year high of $23.10. The stock has a market capitalization of $3.72 billion, a PE ratio of 4.33, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76. The business has a 50 day simple moving average of $15.26 and a 200-day simple moving average of $16.12. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73.

Remove Ads

Organon & Co. (NYSE:OGN - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. On average, equities analysts forecast that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 7.77%. The ex-dividend date was Monday, February 24th. Organon & Co.'s dividend payout ratio is 33.63%.

Wall Street Analyst Weigh In

Several brokerages have commented on OGN. TD Cowen raised shares of Organon & Co. to a "hold" rating in a research report on Wednesday, January 15th. Morgan Stanley reduced their price target on Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating for the company in a research report on Friday, February 14th. Finally, Barclays lowered their target price on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Organon & Co. has an average rating of "Hold" and a consensus price target of $20.80.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.